VectivBio Holding AG (VECT) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
VectivBio Holding AG stock (VECT) is currently trading at $16.85. VectivBio Holding AG PS ratio (Price-to-Sales) is 21.08. Analyst consensus price target for VECT is $18.33. WallStSmart rates VECT as Sell.
- VECT PE ratio analysis and historical PE chart
- VECT PS ratio (Price-to-Sales) history and trend
- VECT intrinsic value — DCF, Graham Number, EPV models
- VECT stock price prediction 2025 2026 2027 2028 2029 2030
- VECT fair value vs current price
- VECT insider transactions and insider buying
- Is VECT undervalued or overvalued?
- VectivBio Holding AG financial analysis — revenue, earnings, cash flow
- VECT Piotroski F-Score and Altman Z-Score
- VECT analyst price target and Smart Rating
VectivBio Holding AG
📊 No data available
Try selecting a different time range
Smart Analysis
VectivBio Holding AG (VECT) · 6 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in institutional own.. Concerns around return on equity and operating margin. Significant fundamental concerns warrant caution or avoidance.
VectivBio Holding AG (VECT) Key Strengths (1)
83.80% of shares held by major funds and institutions
Supporting Valuation Data
VectivBio Holding AG (VECT) Areas to Watch (5)
Company is destroying shareholder value
Losing money on operations
Very expensive at 21.1x annual revenue
Premium pricing at 3.6x book value
Small-cap company with higher risk but more growth potential
Supporting Valuation Data
VectivBio Holding AG (VECT) Detailed Analysis Report
Overall Assessment
This company scores 19/100 in our Smart Analysis, earning a F grade. Out of 6 metrics analyzed, 1 register as strengths (avg 10.0/10) while 5 fall into concern territory (avg 2.2/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own..
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Price/Sales. Some valuation metrics including Price/Sales (21.08), Price/Book (3.62) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -56.90%, Operating Margin at -294.50%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -56.90% needing improvement to support the investment thesis. Third, top-line growth trajectory.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
VECT Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
VECT's Price-to-Sales ratio of 21.08x sits near its historical average of 21.08x (0th percentile), suggesting the market is pricing in steady-state growth. The current valuation is 0% below its historical high of 21.08x set in Mar 2026, and 0% above its historical low of 21.08x in Mar 2026.
WallStSmart Analysis Synopsis
Data-driven financial summary for VectivBio Holding AG (VECT) · HEALTHCARE › PHARMACEUTICALS
The Big Picture
VectivBio Holding AG operates as a stable business with moderate growth and solid fundamentals.
Key Findings
Generating 54M in free cash flow and 54M in operating cash flow. Earnings are translating into actual cash generation.
Debt-to-equity ratio of 0.05 indicates a conservative balance sheet with 221M in cash.
What to Watch Next
Sector dynamics: monitor PHARMACEUTICALS industry trends, competitive moves, and regulatory changes that could impact VectivBio Holding AG.
Bottom Line
VectivBio Holding AG offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About VectivBio Holding AG(VECT)
NASDAQ
HEALTHCARE
PHARMACEUTICALS
USA
VectivBio Holding AG, a clinical-stage biopharmaceutical company, focuses on the discovery, development and commercialization of treatments for rare conditions. The company is headquartered in Basel, Switzerland.